Israel Science Foundation   Report issue

Foundation Phase 2
Founded: Jerusalem Israel (1972)

Organization Overview

First Clinical Trial
2002
NCT00162435
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Israel Science Foundation

Active Ingredients

Drugs in Phase 2 Trials (2)

d-serine (1 trial)

olanzapine (zyprexa) (1 trial)

Drugs in Other Trials (3)

duloxetine (Cymbalta) (1 trial)

pregabalin (lyrica) (1 trial)

warfarin (coumadin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schizophrenia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5